Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-AI-18-022

Advancing mAbs to Achieve a Drug-free Sustained HIV Virologic Remission (U01 Clinical Trial Required)

Closed on October 9, 2019.

Posted
June 28, 2018
Close date
October 9, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,678,283 in first-year total cost, median $1,678,283.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 CD-A (M1)]1

Most frequent institutions

  1. ROCKEFELLER UNIVERSITY1
Competing awards under RFA-AI-18-022 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019Immunologic control of HIV-1 through combination bNAbs and biologics.1U01AI145921-01CASKEY, MARINAROCKEFELLER UNIVERSITY, NY$1,678,283ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works